Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)
← Improved lifelines needed for all lines: real-world treatment patterns and attrition rates in US patients with non-driver mutation metastatic non-small cell lung cancerReal-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Been Treated with Luspatercept →